Delivery Order HHSN261201200033I-HHSN26100008
Award Date
9/24/15
Potential Completion Date
9/23/19
Potential Value
$4.1M
Federal Agency
National Cancer Institute
Awardee
University Of Wisconsin System
Ultimate Awardee
University Of Wisconsin System
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Madison, WI 53715, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
5
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Wisconsin - Madison, operating as Research and Sponsored Programs within the University of Wisconsin System. The $418,872.19 contract is for research and development related to the Cancer Prevention Agent Development Program, which is focused on early phase clinical research. This contract is a delivery order under the Cancer...
The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a $709,235 Delivery Order contract to the University of Wisconsin System for core infrastructure support under the Cancer Prevention Agent Development Program 2012-2017 contract. This Cost-No-Fee contract does not have a set-aside designation and was awarded on September 23, 2014, with a completion date of September 23, 2015. The University of Wisconsin System, through its University...
This federal contract award, valued at $261,352.00, was issued by the National Cancer Institute (NCI) to the University of Wisconsin System (UW System) to conduct a randomized, double-blind, Phase I dose-escalation study of a novel retinoid called 9CUAB30. The contract is part of the NCI's Cancer Prevention Agent Development Program, which focuses on early-phase clinical research. As the prime contractor, the UW System will be responsible for performing the clinical study at its University of...
This is a $2,453,803.00 delivery order contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to the University of Wisconsin System for the "CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH". The contract is part of the larger "Cancer Prevention Agent Development Program 2012-2017" contract vehicle and is for cost-no-fee work. The contract does not have a set-aside designation and is...
This $655,319.62 federal contract was awarded by the National Cancer Institute, which is part of the U.S. Department of Health and Human Services, to the University of Wisconsin System's division at the University of Wisconsin - Madison. The contract is for a Phase 1B clinical study to evaluate the biological effect of an early-stage breast cancer prevention agent. This award is part of the Cancer Prevention Agent Development Program, which supports early-phase clinical research. The contract...
This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the U.S. government, to the University of Wisconsin System. The $1,214,305 contract is for a Phase I clinical trial to evaluate the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) that targets three breast cancer antigens (IGFBP-2, HER2, and IGF-IR). The contract is part of NCI's Cancer Prevention Agent Development Program, which focuses on early-stage clinical research. The...
This is a definitive contract awarded by the National Cancer Institute (NCI), a civilian agency of the Department of Health and Human Services (HHS), to the University of Wisconsin Hospitals and Clinics Authority (UWHCA) on September 15, 1999. The contract, valued at $2,765,970.00, is for a randomized controlled Phase II clinical trial to study the modulation of intermediate endpoint biomarkers, as described in Workstatement No. 61. The contract does not have a set-aside designation and is...
This federal contract award was issued by the National Cancer Institute (NCI), a part of the U.S. Department of Health and Human Services, to ICF Macro Inc., a subsidiary of ICF International, Inc. The $22,080,493 contract, which does not have a set-aside designation, is for a Campaigns and Monitoring period of performance from September 2016 to September 2017 to expand and promote NCI's tobacco cessation resources. The contract is a Blanket Purchase Agreement (BPA) Call and is priced on a...
This is a $460,975.01 firm fixed-price delivery order awarded by the National Institutes of Health (NIH) National Cancer Institute to The Medical College of Wisconsin, Inc. (MCW), a private medical school and graduate institution. The contract is part of the NIH's "PREVENT Cancer Program (PREVENT)" and supports the "Preclinical Prevent Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers" major program. No set-aside designation was used. Through past...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Wisconsin System for cellular assays services. The $3,200.00 firm fixed price purchase order contract does not have a set-aside designation, indicating open competition. The University of Wisconsin System, a leading public research institution, has a robust portfolio of federal contract and grant work spanning...